Abstract
The gene encoding isocitrate dehydrogenase (IDH) is somatically mutated predominantly in secondary glioblastoma multiforme. Glioma-specific mutations in IDH1 always produced a single amino acid substitution at R132, but mutations in IDH2 were exclusively at R172 which was the analogous site to R132 in IDH1. Mutations of IDH1 and IDH2 led to simultaneous loss and gain of activities in the production of α-ketoglutarate and 2-hydroxyglutarate, respectively. Matrix metalloproteinases (MMPs) are zinc-dependent endoproteinases involved in the degradation of the extracellular matrix. The exact role of IDH2 mutant on MMPs activity and cell migration has not been fully studied. Here, we show that in response to IDH2 mutations, low levels of α-ketoglutarate increased the stabilization of HIF-1α which can contribute to tumor growth. Moreover, mutant IDH2-induced HIF-1α improved the secretion levels of pro-MMP-2 and pro-MMP-9 as well as the conversion from pro-MMP-2 to its active form, giving C6 glioma cells a higher migration potential. The HIF-1α pathway is probably a critical pathway for release of MMPs in the glioma cancer harboring IDH mutant.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Gliomas are the most common type of human brain tumors and contain specific histological subtypes. The major ones among these are astrocytomas, oligodendrogliomas and ependymomas (Fu et al. 2011b). WHO has classified gliomas into four clinical grades on the basis of histology and prognosis. The grade IV glioma, known as glioblastoma multiforme (GBM), is the most prevalent and malignant primary brain tumor in adults (Ji et al. 2011). Patients with it have a median survival of less than 1 year (Badiga et al. 2011). GBM can develop either de novo (primary GBM) or through progression from low grade tumors (secondary GBM) (Zhao et al. 2009).
Matrix metalloproteinases (MMPs) are a family of zinc-dependent endoproteinases involved in the degradation of the extracellular matrix (ECM). They play roles in normal tissue remodeling during embryonic development, angiogenesis, ovulation, mammary, gland involution and wound healing (Ranogajec et al. 2011; Castro et al. 2011). The expression level of MMPs correlates with the invasion of cancer cells because the degradation of the ECM is essential for tumor angiogenesis, invasion, and metastasis (Gladson 1999; Shao et al. 2011; Li et al. 2011; Lee et al. 2011). Amongst many MMPs that have been identified, MMP-2 (gelatinase-A) and MMP-9 (gelatinase-B) have been hypothesized to be key enzymes as they degrade type IV collagen (the main component of ECM) (Chen et al. 2011; Ranogajec et al. 2011; Berg et al. 2011). Specifically, MMP-2 is up-regulated in gliomas and related cancers, but its expression level is trivial in normal brain tissue (Deshane et al. 2003).
A recent cancer genome-sequencing project revealed that the gene encoding isocitrate dehydrogenases 1 (IDH1) was somatically mutated predominantly in secondary GBM (Fu et al. 2010; Zhao et al. 2009). However, the frequency of IDH2 mutation in these gliomas was low. The human genome has five genes coding for three distinct catalytic isozymes of IDH: IDH1, IDH2 and IDH3. IDH enzymes catalyze the oxidative decarboxylation of isocitrate (ICT) into α-ketoglutarate (α-KG); IDH1 and IDH2 are NADP+-dependent and IDH3 is NAD+-dependent. Both IDH2 and IDH3 enzymes are localized in the mitochondria, whereas IDH1 is localized in the cytoplasm and peroxisomes (Fu et al. 2011b; Zhao et al. 2009). Intriguingly, glioma-specific mutations in IDH1 always produced a single amino acid substitution at R132, whereas mutations in IDH2 were exclusively at R172. IDH1 and IDH2 mutations led to simultaneous loss and gain of activities in the production of α-KG and 2-hydroxyglutarate (2-HG), respectively. In response to IDH1 mutations, low level of α-KG resulted in increasing the stabilization of HIF-1α which could contribute to tumor growth (Zhao et al. 2009).
In our previous study, we reported that mutations of IDH1 and IDH2 were not detected in the rat C6 gliomas cell line model, suggesting that these mutations were not required for the development of glioblastoma induced by N,N′-nitroso-methylurea (Fu et al. 2011b). Moreover, we concluded that the low NADPH levels could sensitize tumors to chemotherapy and account for the prolonged survival of patients harboring the mutations. These data extrapolated potential importance of the in vitro rat C6 glioma cell model and showed that the IDH2R172G mutation in glioma might give a benefit to traditional chemotherapy of this cancer. Invasion of glioma cells into adjacent brain structures occurs through the activation of multigenic programs, including MMPs which degrade ECM to overcome the ECM barrier at the invasive fronts of tumors (Giese and Westphal 1996). Although IDH2 mutations in gliomas were low (Zhao et al. 2009), the function study on IDH2 mutations was needed for the diagnosis, prognosis, and treatment of patients with these tumors. Moreover, the exact role the mutant IDH2 plays on MMPs activity and cell migration has not been fully studied yet. In the present study, the effect of IDH2R172G on rat C6 glioma cells migration is analyzed at the cellular level and the role of HIF-1α pathway in MMPs release in the glioma cancer harboring IDH2 mutant is discussed.
Materials and methods
Materials
pEGFP-N1-IDH2 and pEGFP-N1-IDH2R172G were constructed in our laboratory (Fu et al. 2011b). Rat C6 glioma cells were kindly provided by Prof. Wang (Institute of Clinical Medicine, Renmin Hospital, Yunyang Medical College, Shiyan, Hubei, China). Dulbecco’s modified Eagle’s medium (DMEM) was from Gibco BRL, calf serum was from Hangzhou Evergreen Corp. Lipofactamine 2000 was from Invitrogen Antibody of rabbit-anti-rattus HIF-1α and fluorescent TRITC labeled goat-anti-rabbit IgG were purchased from Wuhan Boster Crop. All reagents used are of highest molecular grade.
Cell culture
Cell cultures were prepared and maintained according to standard cell culture procedures. The rat C6 glioma cells were cultured at 37°C in a humidified atmosphere of 5% CO2 in DMEM supplemented with 10% (v/v) heat-inactivated calf serum.
Transfection of recombinant plasmids
C6 cells were cultured in the 6-, 96- and 24-well microtiter plates in immunofluorescence location assay, gelatin zymography assay and in vitro wound healing assay, respectively. For transient transfection, cells were harvested by pancreatin digestion and seeded on microtiter plates. Transfection of plasmids (pEGFP-N1, pEGFP-N1-IDH2 and pEGFP-N1-IDH2R172G) was performed with Lipofactamine 2000 according to manufacturer’s instructions: for six-well microtiter plates, cells were incubated with 4 μg plasmid DNA and 10 μl Lipofectamine 2000 in Opti-MEM overnight before being analyzed. In the same way, for 96-well microtiter plates and 24-well microtiter plates, cells were incubated with 0.2 μg plasmid DNA and 0.5 μl Lipofectamine 2000 or 0.8 μg plasmid DNA and 2 μl Lipofectamine 2000, respectively.
Immunofluorescence location assay for HIF-1α
The effect of EGFP, EGFP-IDH2 and EGFP-IDH2R172G on the stabilization of HIF-1α was analyzed by immunofluorescence location assay. C6 cells transfected with recombinant plasmids were fixed with 4% (v/v) paraformaldehyde in PBS, washed with PBS, then permeabilized with 0.3% Triton X-100 for 20 min. Cells were then washed gently with PBS and blocked with BSA in PBS for 1 h. Rabbit-anti-rattus HIF-1α (1:100) antibody was added and incubated at 4°C overnight. The antibody of fluorescent TRITC labeled goat-anti-rabbit IgG (1:64) was then added for 1 h at room temperature. Coverslips are then washed with PBS, mounted onto slides and observed with a laser scanning confocal microscope.
Gelatin zymography assay
Gelatinolytic activity of MMP-2 and MMP-9 was analyzed by gelatin zymography assay. C6 cells transfected with recombinant plasmids were incubated for 24 h. Culture media were then changed into serum-free cell culture media. To understand the effect of HIF-1α on MMPs activity in the glioma cells harboring IDH2 mutant, CoCl2 was used for its induction as mentioned earlier (Zhao et al. 2009). As a control sample, CoCl2 was added into the serum-free cell culture media at 200 μM. Serum-free media conditioned for 24 h were subjected to 10% (v/v) SDS-PAGE containing 0.1% gelatin. The gel was incubated twice (for 30 min at room temperature) in 2.5% Triton X-100. The gel was then incubated in activation buffer (5 mM CaCl2, 1 μM ZnCl2, and 0.005% Brij, 50 mM Tris/HCl, pH 8.0) at 37°C overnight, stained with Coomassie Brilliant Blue R-250 and briefly destained in 10% (v/v) acetic acid and 40% (v/v) methanol (Fu et al. 2011a). Gelatinolytic activity of MMPs is detected as transparent bands on the blue background.
In vitro wound healing assay
The effect of EGFP, EGFP-IDH2 and EGFP-IDH2R172G on cell migration was examined using in vitro wound healing assay. After transfection with recombinant plasmids for 24 h, a ‘scratch’ was introduced by scraping the C6 cells monolayer with a p200 pipette tip and then washed gently three times with cell culture media to remove cell debris. As a control group, CoCl2 was added into the serum-free cell culture media before the cells were scratched. The cells were then cultured by serum-free culture media. Percent migration rate (MR%) was calculated as: MR% = (1 − T/C) × 100%, where T and C represent, respectively, the scrape distance at the indicated treatment times and at the previous treatment time.
Results and discussion
IDH2R172G increases the stabilization of HIF-1α
Compared to the EGFP and IDH2 treatment groups, the amounts of fluorescence of IDH2R172G and HIF-1α in IDH2R172G treatment group were significantly elevated (Fig. 1). This demonstrates that: (1) mutant IDH2 can elevate the stabilization of HIF-1α, and (2) improve the growth rate of C6 cells. The link between IDH2R172G, HIF-1α and tumor growth was confirmed: mutant IDH2 improved tumor growth by elevating the stabilization of HIF-1α. This link highlights an emerging theme in which mutationally-altered metabolic enzymes are thought to contribute to tumor growth by stimulating HIF-1α pathway.
IDH2R172G improves the secretion levels of pro-MMP-2 and 9
Matrix metalloproteinases production in response to induced HIF-1α has not been elucidated in the glioma cells harboring IDH2 mutant. CoCl2 treatment was used as a control group since previous results showed that CoCl2 at 200 μM induced HIF-1α in U-87MG cells (Zhao et al. 2009). As shown in Fig. 2a, transparent bands of pro-MMP-9 (~90 kDa), pro-MMP-2 (~70 kDa) and MMP-2 (~60 kDa) were detected in the gelatin zymography assay. CoCl2-induced HIF-1α increased the protein levels of pro-MMP-2, 9 in the conditioned media of cells. The activity of pro-MMP-2, 9 was elevated in the CoCl2 and IDH2R172G treatment groups compared to that in the IDH2 and EGFP treatment groups which demonstrates that mutant IDH2 can also elevate the secretion levels of MMP-2 and MMP-9 by stimulating HIF-1α pathway according to the results obtained in above section. Moreover, IDH2R172G induced HIF-1α also increased the conversion from pro-MMP-2 to its active form (Fig. 2b).
IDH2R172G accelerates C6 glioma cells migration
Matrix metalloproteinases-2 and MMP-9 have been hypothesized to be key enzymes responsible for the degradation of type IV collagen, the main component of ECM. Presumably, these two enzymes may be critical for C6 glioma cells migration or metastasis. As shown in Fig. 3, compared to that of the EGFP and IDH2 treatment groups, migration rates of C6 glioma cells were promoted by approx. 47% in the presence of both IDH2R172G and CoCl2 at 16 h. These results show that: (1) IDH2R172G displays a higher activity in promoting cell migration than IDH2 does, and (2) MMP-2 and MMP-9 are critical for C6 cell metastasis and angiogenesis at least in this aspect.
Our recent studies have shown the relations of mutated IDH2, NADPH and chemotherapy sensitivity in C6 gliomas (Fu et al. 2011b): (1) IDH2R172G can sensitize glioma sensitivity to chemotherapy through NADPH levels; (2) IDH2R172G can give a benefit to traditional chemotherapy of glioma. In the present study, the relationships of mutated IDH2, HIF-1α, MMPs and glioma migration were disclosed: (1) HIF-1α pathway is critical in MMPs release in glioma cancer harboring IDH2 mutant; (2) Mutant IDH2-induced HIF-1α can improve the secretion levels of MMP-2 and 9; 3) Mutant IDH2-induced HIF-1α provides glioma cells with a higher migration potential via up-regulation of MMP-2 and 9. This study may therefore serve as an important complement to existing research on this topic.
References
Badiga AV, Chetty C, Kesanakurti D, Are D, Gujrati M, Klopfenstein JD, Dinh DH, Rao JS (2011) MMP-2 siRNA inhibits radiation-enhanced invasiveness in glioma cells. PloS One 6:e20614
Berg G, Miksztowicz V, Schreier L (2011) Metalloproteinases in metabolic syndrome. Clin Chim Acta 412:1731–1739
Castro MM, Kandasamy AD, Youssef N, Schulz R (2011) Matrix metalloproteinase inhibitor properties of tetracyclines: therapeutic potential in cardiovascular diseases. Pharmacol Res 64(6):551–560
Chen RX, Cui JF, Xu CD, Xue TC, Guo K, Gao DM, Liu YK, Ye SL, Ren ZG (2011) The significance of MMP-9 over MMP-2 in HCC invasiveness and recurrence of hepatocellular carcinoma after curative resection. Ann Surg Oncol (Online)
Deshane J, Garner CC, Sontheimer H (2003) Chlorotoxin inhibits glioma cell invasion via matrix metalloproteinase-2. J Biol Chem 278:4135–4144
Fu YJ, Huang R, Du J, Yang RJ, An N, Liang AH (2010) Glioma-derived mutations in IDH: from mechanism to potential therapy. Biochem Biophys Res Commun 397:127–130
Fu YJ, An N, Chan KG, Wu YB, Zheng SH, Liang AH (2011a) A model of BmK CT in inhibiting glioma cell migration via matrix metalloproteinase-2 from experimental and molecular dynamics simulation study. Biotechnol Lett 33:1309–1317
Fu YJ, Huang R, Zheng YL, Zhang ZY, Liang AH (2011b) Glioma-derived mutations in isocitrate dehydrogenase 2 beneficial to traditional chemotherapy. Biochem Biophys Res Commun 410:218–223
Giese A, Westphal M (1996) Glioma invasion in the central nervous system. Neurosurgery 39:235–250
Gladson CL (1999) The extracelular matrix of gliomas: modulation of cell function. J Neuropathol Exp Neurol 58:1029–1040
Ji HT, Wang J, Fang B, Fang X, Lu Z (2011) α-Catenin inhibits glioma cell migration, invasion, and proliferation by suppression of β-catenin transactivation. J Neurooncol 103:445–451
Lee SY, Park SY, Kim SH, Choi EC (2011) Expression of matrix metalloproteiases and their inhibition in squamous cell carcinoma of the tonsil and their clinical significance. Clin Exp Otorhinolaryngol 4:88–94
Li LW, Chen P, Ling Y, Song XM, Lu ZJ, He QH, Li ZY, Lu N, Guo QL (2011) Inhibitory effects of GL-V9 on the invasion of human breast carcinoma cells by downregulating the expression and activity of matrix metalloproteinase-2/9. Eur J Pharm Sci 43:393–399
Ranogajec I, Razumovic JJ, Puzovic V, Gabrilovac J (2011) Prognostic value of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) and aminopeptidase N/CD13 in breast cancer patients. Med Oncol (Online)
Shao WL, Wang W, Xiong XG, Cao C, Yan TD, Chen GQ, Chen HZ, Yin WQ, Liu J, Gu YY, Mo MC, He JX (2011) Prognostic impact of MMP-2 and MMP-9 expression in pathologic stage IA non-small cell lung cancer. J Surg Oncol 104(7):841–846
Zhao SM, Lin Y, Xu W, Jiang WQ, Zha ZY, Wang P, Yu W, Li ZQ, Gong LL, Peng YJ, Ding JP, Lei QY, Guan KL, Xiong Y (2009) Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1α. Science 324:261–265
Acknowledgments
This project was supported by grants from the “National Natural Science Foundation of China” (No. 30700534, 31071924), the “Natural Science Foundation of Shanxi Province” (2008021039, 2010011040-1), and “Shanxi Scholarship Council of China”.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fu, Y., Zheng, Y., Li, K. et al. Mutations in isocitrate dehydrogenase 2 accelerate glioma cell migration via matrix metalloproteinase-2 and 9. Biotechnol Lett 34, 441–446 (2012). https://doi.org/10.1007/s10529-011-0800-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10529-011-0800-8